Iovance Biotherapeutics

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Iovance Biotherapeutics progresses on BLA for lifileucel, faces recruitment challenges

Iovance Biotherapeutics is on track with BLA completion expected this quarter, strong pipeline progress, and manufacturing capacity expansion. Challenges include study recruitment uncertainties and the ongoing CEO search. Opportunities exist in new program data releases, European expansion, and pivotal study enrollment.

Iovance Biotherapeutics advances TIL therapy pipeline with strong financials

Iovance Biotherapeutics is on track with key milestones in TIL therapy development and commercialization.
The company's financial position is stable, with strategic investments supporting future growth.
Challenges include operational efficiency, FDA interactions, and trial progress management.
Opportunities lie in international trials, market expansion, and revenue growth post-launch.

Iovance Biotherapeutics reports Q2 loss, eyes lifileucel FDA review

Iovance Biotherapeutics faces financial challenges with a significant net loss in Q2 2023, despite positive milestones and revenue from Proleukin sales.
The company's TIL therapy pipeline shows promise with progress in key clinical trials, while opportunities exist for market differentiation and revenue growth.
Challenges include ongoing financial losses, longer timelines for pivotal studies, and potential delays in trial enrollment, requiring strategic management.

Iovance Biotherapeutics progresses on Lifileucel commercialization and pipeline expansion

Iovance Biotherapeutics is making significant strides in advancing its pipeline and commercialization efforts, with a strong focus on FDA approval for Lifileucel and expanding into key markets. The company faces challenges in labeling discussions and efficacy benchmarks but has opportunities in European marketing, new therapy programs, and potential partnerships for international growth.

Iovance Biotherapeutics excels with Amtagvi approval and clinical progress

Iovance Biotherapeutics showcased strong performance with the FDA approval of Amtagvi and progress in clinical trials, positioning the company for growth.
While facing challenges in scaling operations and regulatory hurdles, the company's focus on efficiency and clinical research strengths bode well for the future.
With opportunities in label expansion, market penetration, and revenue growth, Iovance is poised to capitalize on its innovative therapies and drive value for stakeholders.

Iovance Biotherapeutics reports Q1 loss, Amtagvi launch success

Iovance Biotherapeutics shows promising performance with a focus on Amtagvi's commercial success and pipeline advancements.
Strengths include positive reimbursement trends, successful patient selection processes, and efficient manufacturing operations.
Challenges lie in patient screening failures, financial clearance issues, and variability in bridging therapy usage.
Opportunities for growth include market expansion, high patient conversion rates, and accelerated submission processes for new therapies.

Iovance Biotherapeutics (IOVA) exceeds Q3 revenue targets, eyes global expansion

Iovance Biotherapeutics (IOVA) had a strong Q3 performance, exceeding revenue guidance and showcasing growth potential.
The company's focus on Amtagvi and global expansion presents opportunities for revenue diversification and market penetration.
Challenges lie in maintaining adoption rates, meeting revenue targets, and effectively managing increased manufacturing capacity.
Overall, IOVA's strategic initiatives position it for continued growth and success in the biopharmaceutical market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN CARLOS, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that new interim clinical data for the tumor infiltrating lymphocyte (TIL) therapy LN-145 in combination with pembrolizumab in head and neck squamous cell carcinoma (HNSCC) will be presented at the 35th Anniversary Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The SITC 35th Annual Meeting will be held virtually from November 9-14, 2020. Details of the poster are as follows:

Iovance Biotherapeutics to Present Clinical Data in Head and Neck Cancer at Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting

NEW YORK, Oct. 9, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980....

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA

Iovance (IOVA) delays its application to the FDA for a tumor-infiltrating lymphocyte (TIL) therapy, lifileucel, for the treatment of metastaic melanoma until later in 2021.

Iovance Stock Down on Delay in Filing for Melanoma Candidate

Shares of Iovance Biotherapeutics Inc. iova were down 20.0% in premarket trading on Tuesday, the day after the biotechnology company said it plans to now submit an application to the Food and Drug Administration next year after the regulator took issue with its current application. Iovance, which is seeking approval for an experimental metastatic melanoma drug, said it does not agree with the FDA on the required potency assays, which is required for its biologics license apppliation submission.

Iovance's stock tumbles over questions about regulatory submission for melanoma drug

SAN CARLOS, Calif., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the following conferences.

Iovance Biotherapeutics to Present at Upcoming October Conferences

SAN CARLOS, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today provided a regulatory update for its tumor-infiltrating lymphocyte (TIL) therapy lifileucel in metastatic melanoma. In preparation for the planned Biologics License Application (BLA) submission for lifileucel, the Company has been engaged in discussions with the U.S. Food and Drug Administration (FDA), including a recent Type B meeting, regarding the requirements and timing of certain information that would be provided as part of its BLA submission. 

Iovance Biotherapeutics Provides Update for Lifileucel in Metastatic Melanoma

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock?

Iovance Biotherapeutics (IOVA) Down 1.6% Since Last Earnings Report: Can It Rebound?

Iovance's (IOVA) second-quarter bottom line beats estimates. The company is progressing well with its lead pipeline candidates.

Iovance (IOVA) Q2 Earnings Beat Estimates, Pipeline in Focus

SAN CARLOS, Calif., Aug.  07, 2020  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the BTIG Biotechnology Conference 2020 (Virtual) on August 11, 2020 at 2:30pm ET.

Iovance Biotherapeutics to Present at BTIG Biotechnology Conference 2020

Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q2 2020 Results - Earnings Call Transcript

Enrollment Completed in Pivotal Cohort 1 of C-145-04 Cervical Cancer Study Enrollment Completed in Pivotal Cohort 1 of C-145-04 Cervical Cancer Study

Iovance Biotherapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate Update

SAN CARLOS, Calif., July  23, 2020  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its second quarter 2020 financial results on Thursday, August 6, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. EDT.

Iovance Biotherapeutics to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Thursday, August 6, 2020

Amgen

Anthem

Bristol-Myers

Guardant Health Inc

IQVIA Hlds

Medtronic

Veeva Systems

West Pharmaceutical Services

Acceleron Pharma

The pandemic has put the health care industry under a global spotlight.

10 Stocks to Invest in the Health Care Revolution

After rumors swirled about a potential acquisition, it now appears the biopharma is transitioning to commercial operations as a standalone company.

Is Iovance Biotherapeutics a Buy?

Adding One More Dimension In Solid Tumor Therapy - Iovance Biotherapeutics

SAN CARLOS, Calif., June  08, 2020  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the following virtual conferences in June:

Iovance Biotherapeutics to Present at Upcoming June Conferences

Why Is Iovance Biotherapeutics (IOVA) Down 1.4% Since Last Earnings Report?

Offering Includes Exercise in Full of the Underwriters’ Option to Purchase an Additional 2.5 Million Shares of Common Stock Offering Includes Exercise in Full of the Underwriters’ Option to Purchase an Additional 2.5 Million Shares of Common Stock

Iovance Biotherapeutics, Inc. Announces Closing of $603.7 Million Common Stock Public Offering

Iovance Biotherapeutics (IOVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Iovance Biotherapeutics (IOVA) Upgraded to Buy: Here's What You Should Know

Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up

Iovance Presents Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel in Advanced Melanoma at ASCO Scientific Program

SAN CARLOS, Calif., May  28, 2020  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq:IOVA) (“Iovance” or “Company”), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today announced the pricing of an underwritten public offering of 16,935,484 shares of its common stock at a public offering price of $31.00 per share.  The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Iovance, are expected to be approximately $525 million.  In addition, Iovance has granted the underwriters a 30-day option to purchase up to 2,540,322 additional shares of common stock at the public offering price, less the underwriting discounts and commissions.  The offering is expected to close on or about June 2, 2020, subject to customary closing conditions.

Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately $525 Million of Common Stock

The biotech company is looking to raise up to $575 million ahead of its transition to commercial-stage operations.

Iovance Biotherapeutics Couples Data Release With Stock Offering

Iovance Biotherapeutics (NASDA:IOVA) shares are trading lower on Thursday, after the company announced a $500 million proposed public offering of common stock.

Why Iovance Biotherapeutics Is Trading Lower Today

Iovance unveiled promising test results for a cancer treatment, but IOVA stock tumbled Thursday on a subsequent public offering. Proceeds will be used, in part, to launch the drug.

A Public Offering Undercut This Biotech Stock's Promising Cancer Data

Cohort 4 Early Data Shows 32.4% ORR by Investigator Assessment at 5.3 Months of Median Study Follow up

News for Iovance Biotherapeutics Stock (IOVA)